Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study-PR Newswire APAC

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study-PR Newswire APAC

MELBOURNE, Australia and SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States.

BioMUSE is a natural history study that aims to track the progression of...

Read more: Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study-PR Newswire APAC

More Articles …

  1. Tech Mahindra Acquires Momenton and Tenzing Ltd to Bolster Capabilities in Financial Services in ANZ-PR Newswire APAC
  2. Major survey finds Australians aware of cyber threats but not fully prepared for them-PR Newswire APAC
  3. Crown Equipment Celebrates 75 Years of Customer Excellence-PR Newswire APAC
  4. China Matters documents stories of Global Photographers' COVID-19 Observation-PR Newswire APAC
  5. New Data On Mayne Pharma's Tolsura® (SUBA®-itraconazole) Presented At IDWeek 2020-PR Newswire APAC
  6. TerraPay strengthens its entry in North America with FINTRAC Canada MSB License-PR Newswire APAC
  7. Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies-PR Newswire APAC
  8. Zayed Award for Human Fraternity Judging Committee meets with Pope-PR Newswire APAC
  9. Azura Ophthalmics raises $28m for registration studies for treatment of leading cause of dry eye disease-PR Newswire APAC
  10. Ferguson Hyams Multi-Strategy Fund (FHMSF) Added to Quilter and Clearstream Platforms-PR Newswire APAC